IL2 and neoplasm: Mice receiving ACT + NKTR-214 showed a median tumor growth delay (evaluated as time to reach a tumor volume of 1000 mm3) of 42 days compared to ACT + IL-2 or ACT + vehicle (19.5 and 11 days, respectively, Fig. 1c).